Therefore, we suggest that PPARγ is an important regulator of ethanol-induced hepatic steatosis, and that the development of an MGAT1 inhibitor could be an effective therapy for treating alcoholic or non-alcoholic hepatic steatosis. Here, MGAT1 is linked to fatty liver disease.